Abfero Pharmaceuticals Announces Initiation of Phase 1 Study for Lead Iron Chelator
UF startup AbFero Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of its lead iron chelator, SP-420, in myelodysplastic (MDS) and myelofibrosis patients (MF) with transfusional iron overload (TIO).
AbFero Pharmaceuticals Announces Funding From Cure Parkinson’s for Lead Compound SP-420
AbFero Ltd., a subsidiary of UF startup AbFero Pharmaceuticals, Inc., a privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload, announced the award of a grant from Cure Parkinson's for the development of their lead, brain-penetrant iron chelating agent, SP-420, as a disease modifying therapy for Parkinson's disease (PD).
AbFero to Receive € 2M Eurostars Funding for Parkinson’s Disease Therapy
AbFero Ltd., a subsidiary of UF startup AbFero Pharmaceuticals, Inc., a privately-held clinical-stage pharmaceutical company dedicated to treating diseases of iron overload, announced the funding of approximately € 2M from EUREKA Eurostars for the development of iron-chelating compounds including their lead agent, SP-420, as a disease-modifying therapy for Parkinson's disease.
AbFero Announces PK Study Results for SP-420 in Transfusional Iron Overload – Proceeds With Phase 1–2 Trial of Iron Chelator
UF startup AbFero Pharmaceuticals, Inc., a privately-held clinical-stage pharmaceutical company dedicated to treating diseases of iron overload, announced it completed analysis of... Read More
UF Innovate | Ventures Invests in AbFero Pharmaceuticals
The University of Florida’s newly established venture fund, directed by UF Innovate | Ventures, has invested part of its inaugural fund in... Read More
